Related Experiment Video
Updated: Jun 18, 2025

Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs
Published on: July 6, 2015
Glycyrrhizin intake higher than the current international guidelines has no detectable hypermineralocorticoid-like
Adrian Watson1, Elizabeth Fuess2, Jeremy Laxalde1
1Royal Canin SAS, Aimargues, France.
Abstract:
Glycyrrhizin-enriched extracts from licorice root are associated with numerous health benefits and are widely used in phytotherapy. There is evidence that ingesting glycyrrhizin beyond threshold concentrations can impact the metabolism of cortisol, inhibiting its conversion to an inactive form, cortisone, via 11-hydroxysteroid dehydrogenase. A consequence can be a form of hypermineralocorticoidism, with elevated potassium excretion and associated hypertension, as demonstrated in rats and humans. Here, 3 orally dosed concentrations of glycyrrhizin (0.2, 0.4 and 0.6 mg/kg bodyweight/day) were assessed over 28 days in dogs. As the current guidelines reflect a lack of reliable data in this species, our aim was to provide relevant information for doses above the current guidelines. The specific purpose of this study was to demonstrate that an intake of licorice with a known therapeutic benefit to dogs does not cause hypermineralocorticoidism in this species. No changes in blood pressure, nor electrolyte excretion were observed in the dogs given these three glycyrrhizin concentrations.
More Related Videos
07:05Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
Published on: January 3, 2017
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Hypoglycemia and Glucagon
Antihypertensive Drugs: Action of Diuretics
Antihypertensive Drugs: Thiazide-Class Diuretics